Esperion Therapeutics (NASDAQ:ESPR) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. StockNews.com cut Esperion Therapeutics from a strong-buy rating to a buy rating in a report on Friday, May 17th. Needham & Company LLC reissued a buy rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, May 7th. Finally, Bank of America cut Esperion Therapeutics from a neutral rating to an underperform rating and decreased their price objective for the company from $2.90 to $2.50 in a report on Thursday, June 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $8.83.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $2.22 on Friday. The business’s 50-day simple moving average is $2.31 and its two-hundred day simple moving average is $2.39. The company has a market cap of $420.60 million, a PE ratio of -2.24 and a beta of 1.00. Esperion Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.42. The company had revenue of $137.74 million during the quarter, compared to analyst estimates of $53.11 million. As a group, analysts predict that Esperion Therapeutics will post -0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

A number of large investors have recently bought and sold shares of the business. Spire Wealth Management raised its holdings in Esperion Therapeutics by 69.2% in the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 7,267 shares during the period. Private Portfolio Partners LLC purchased a new position in Esperion Therapeutics in the fourth quarter worth approximately $30,000. Herbst Group LLC purchased a new position in Esperion Therapeutics in the first quarter worth approximately $28,000. Summit Financial LLC raised its stake in shares of Esperion Therapeutics by 66.8% in the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 10,355 shares in the last quarter. Finally, PSI Advisors LLC raised its stake in Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 10,500 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.